Interventional device developer Medtronic announced that the first European patients have enrolled in its Clinical Evaluation of SuperDimension Navigation System for Electromagnetic Navigation Bronchoscopy trial, known as Navigate.
The 2,500-patient international study is investigating the long-term effect of the company's superDimension navigation system as an aid in the early detection of lung cancer and subsequent treatment.
Medtronic's superDimension system uses LungGPS technology, which facilitates electromagnetic navigation bronchoscopy procedures, according to the firm. Almost 100,000 of these procedures have been performed globally at more than 600 hospitals, Medtronic said.
Up to 75 centers around the world will enroll patients in the study; more than 22 sites have begun enrolling patients since the effort first began in the U.S. in April 2015, according to Medtronic.
